Early evidence indicated that pharmacological inhibition of HIF1 and HIF2α attenuated hypoxia-induced pulmonary hypertension, RV hypertrophy and PA remodeling by inhibiting intracellular Ca2+ release and pH changes upon hypoxia in PASMC (207). This evidence concerns the gene HIF1A and pulmonary hypertension.